In Other Journals

Ann Gregory
Med J Aust 2003; 179 (7): . || doi: 10.5694/j.1326-5377.2003.tb05601.x
Published online: 6 October 2003

In chronic heart failure, a Lancet commentary advises that patients whose ejection fraction is 40% or less should be prescribed angiotensinreceptor blockers in addition to ACE inhibitors, β-blockers and/or spironolactone.1 Further, angiotensin-receptor β-blockers should be used as an alternative drug in patients with intolerance to ACE inhibitors, and considered in patients whose ejection fraction is more than 40%. The author was commenting on four papers reporting the results of the CHARM — the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity — program.2 CHARM, involving more than 7000 adults with chronic heart failure living in 26 countries including Australia, found that the angiotensinreceptor blocker candesartan reduced cardiovascular deaths and hospital admissions for heart failure.

  • Ann Gregory



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.